Anzeige
+++Kritische Rohstoffe Diese Germanium-Aktie rückt jetzt ins sicherheitspolitische Zentrum Nordamerikas+++

Medacta announces the results of today's Annual General Meeting 07.05.2025, 14:48 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Medacta Group 174,00 EUR -1,36 % Lang & Schwarz

Medacta Group SA / Key word(s): AGMEGM
Medacta announces the results of today's Annual General Meeting

07.05.2025 / 14:48 CET/CEST


Media Release   

Medacta announces the results of today's Annual General Meeting 

  • All proposals of the Board of Directors were approved
  • The distribution of around CHF 13.7 million, or CHF 0.69 per share, was approved
  • Dr. Alberto Siccardi as Chair of the Board of Directors and all other Board members standing for re-election were confirmed  

CASTEL SAN PIETRO, Switzerland, 7 May 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) today announced that its shareholders approved all proposals made by the Board of Directors at today's Annual General Meeting (“AGM”) .

Today's AGM was held with the physical participation of shareholders and took place at the Group premises in Via alla Rossa 6, Rancate - Switzerland. A total  of 17,881,923 shares were represented, either by attending shareholders or by third-party proxy and by the independent proxy, corresponding to approximately 89.41% of Medacta's share capital.

Shareholders approved the distribution of around CHF 13.7 million, or CHF 0.69 per share, half of it to be distributed as dividend out of available earnings and half of it to be distributed out of accumulated reserves from capital contribution.

Alberto Siccardi, Maria Luisa Siccardi Tonolli, Victor Balli, Riccardo Braglia and Philippe Weber were each re-elected as members of the Board of Directors for one-year term of office and Alberto Siccardi was re-elected as chairman of the Board. Medacta's shareholders also re-elected Philippe Weber and Riccardo Braglia as members of the Remuneration Committee for a term of one year.

Further proposals by the Board of Directors that were approved at today's AGM included the following:

  • The approval of the Management Report, the Annual Statutory Financial Statements and the Consolidated Financial Statements for the financial year 2024;
  • The approval of the 2024 Report on non-financial matters;
  • The approval of the Remuneration Report for the financial year 2024;
  • The approval of the appropriation of available earnings as of 31 December 2024 of Medacta Group SA for the financial year 2024;
  • The discharge of the members of the Board of Directors and the Executive Management;
  • The re-election of the independent proxy and the auditors;
  • The maximum aggregate compensations of the Board of Directors and the members of the Executive Management;

The minutes of the 2025 AGM will be available in due course at:
https://www.medacta.com/EN/agm

 

Contact

Medacta International
Anja Pomrehn
Group VP Sustainability and Investor & Media Relations
Telephone: +41 91 696 14 95
Email: pomrehn@medacta.ch

 

About Medacta
Medacta is a global key player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 60 countries. Follow us on Medacta.com, Medacta TV, YouTube, LinkedIn and X.

 



End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 2132324

 
End of News EQS News Service

2132324  07.05.2025 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer